Vystar 10-Q Reveals Going Concern, Material Weaknesses, and Quantifies r3alm JV Terms
VYST has more than doubled off its 52-week low of $0.017 on elevated volume (2.8× avg).
Summary
Vystar's 10-Q shows a going concern warning, material weaknesses, and a 42.7% revenue decline, while quantifying the r3alm JV terms that could add 8.37 million shares.
Key Events · Earnings and Guidance · VYST
-
Going Concern Warning
Cash of $109,845 and a $7.2 million working capital deficit as of June 30, 2026; management states substantial doubt about the company's ability to continue as a going concern.
-
Material Weaknesses Disclosed
Six material weaknesses in internal controls, including lack of segregation of duties, lack of a formal CFO position, and no functioning audit committee.
-
r3alm JV Terms Quantified
The joint venture with Capital Realm to acquire 50% of r3alm involves issuing 8,371 Series B preferred shares convertible into 8,371,000 common shares, fully vested upon proof of IP concept.
-
Revenue Decline
Revenue fell 42.7% to $13,914 for the six months ended June 30, 2026, from $24,272 in the prior year, driven by reduced channel sales.
Analysis · VYST · Manufacturing
Vystar's quarterly report confirms severe financial distress: cash of just $109,845 against a $7.2 million working capital deficit, with management stating substantial doubt about its ability to continue as a going concern. The filing also discloses six material weaknesses in internal controls, including lack of segregation of duties and no functioning audit committee. It quantifies the previously announced r3alm joint venture: 8,371 Series B preferred shares convertible into 8,371,000 common shares, representing significant potential dilution. Revenue fell 42.7% year-over-year for the six months, though net loss narrowed to $590,264 from $965,206. The company is relying on stock subscriptions and related-party advances to fund operations.
At the time of this filing, VYST was trading at $0.10 on OTC in the Manufacturing sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.02 to $0.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.